Indications for: BAXDELA INJECTION
Susceptible acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).
Infuse over 60mins. ≥18yrs: 300mg every 12hrs; or, 300mg every 12hrs then switch to oral tabs 450mg every 12hrs as clinically indicated. ABSSSI: treat for 5–14 days. CABP: treat for 5–10 days. Renal impairment (eGFR 15–29mL/min/1.73m2): 200mg every 12hrs; may switch to oral form as clinically indicated. ESRD (eGFR <15mL/min/1.73m2) or hemodialysis: not recommended (insufficient data). See full labeling.
<18yrs: not recommended.
Serious adverse reactions including tendinitis, tendon rupture, peripheral neuropathy, CNS effects, and exacerbation of myasthenia gravis.
BAXDELA INJECTION Warnings/Precautions:
Increased risk of disabling and potentially irreversible adverse reactions (including tendinitis/tendon rupture [esp. in patients >60yrs, or those with kidney, heart or lung transplants], peripheral neuropathy, or CNS/psychiatric effects); discontinue immediately if signs/symptoms occur. CNS disorders (eg, cerebral arteriosclerosis, epilepsy) that increase seizure risk. History of myasthenia gravis; avoid. Increased risk of aortic aneurysm and dissection (esp. in elderly); reserve use only if no alternatives in patients with history or risk of. Discontinue at 1st sign of skin rash, or any other hypersensitivity. Monitor blood glucose in diabetic patients; discontinue if hypoglycemia occurs. Severe renal impairment receiving IV form: monitor serum creatinine levels, eGFR closely; consider switching to oral form if serum creatinine level increases. Discontinue if eGFR falls <15mL/min/1.73m2. Elderly. Pregnancy. Nursing mothers.
BAXDELA INJECTION Classification:
BAXDELA INJECTION Interactions:
Separate dosing of oral form with magnesium- or aluminum-containing antacids, sucralfate, metal cations, multivitamins containing zinc or iron, or didanosine (buffered forms) by at least 2hrs before or 6hrs after these agents. Increased risk of tendinitis/tendon rupture with corticosteroids. Concomitant antidiabetics may increase blood glucose disturbances. For IV: avoid concomitant solution containing multivalent cations (eg, calcium, magnesium) through same IV line.
Nausea, diarrhea, headache, transaminase elevations, vomiting; tendinitis/tendon rupture, peripheral neuropathy, CNS/psychiatric effects, hypersensitivity reactions, C. difficile-associated diarrhea, dysglycemia, aortic aneurysm/dissection.
Generic Drug Availability:
Tabs—20; Blister packs—20 (2x10 tabs); Single-dose vials—10